Broncus Holding Corp. stock analysis
Want to see HK:2216 full AI Analyst Report?
Broncus Holding Corp. (2216) Stock Price & Analysis
2216 Stock Chart & Stats
- Day’s Range
- HKD 0.53 - HKD 0.56
- 52-Week Range
- HKD 0.53 - HKD 2.75
- Previous Close
- HKD 0.55
- Volume
- N/A
- Average Volume (3M)
- 322.14K
- Market Cap
- HKD 285.52M
- Enterprise Value
- -HKD 503.14M
- Total Cash (Recent Filing)
- HKD 99.28M
- Total Debt (Recent Filing)
- HKD 244.97K
- Price to Earnings (P/E)
- ―
- Beta
- 1.67
- Next Earnings
- Mar 31, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Extremely low leverage reduces refinancing pressure and preserves financial flexibility while the company works to stabilize operations. Positive equity provides a capital base that can support continued investment and absorb losses better than a highly indebted balance sheet.
Specialized Pulmonary Focus
A focused position in respiratory and pulmonary care gives Broncus a clearly defined clinical purpose and development platform. Concentration on minimally invasive bronchoscopic procedures may support deeper expertise and sustained relevance as physicians treat lung disease in specialized settings.
Historical Gross-Margin Capability
The history of solid gross margins indicates that the company has previously demonstrated an ability to generate value above product costs when commercial activity was healthier. Restoring revenue scale could therefore provide a foundation for margin recovery, although execution remains necessary.
Bears Say
Severe Revenue Deterioration
A revenue collapse of this magnitude signals a major loss of commercial traction and materially weakens operating leverage. Even with a specialized product focus, rebuilding demand and restoring a sustainable revenue base could take time, keeping earnings power highly uncertain.
Persistent Unprofitability
Repeated operating and net losses show that the business has not yet converted its technology and clinical focus into sustainable profitability. Negative gross profit in the latest year is especially concerning because it indicates pressure at the core product economics level, not just overhead.
Ongoing Cash Burn
Persistent negative operating and free cash flow means Broncus cannot currently self-fund its operations or growth from internally generated cash. Continued consumption of cash may require external financing and can constrain investment, particularly while revenue and margins remain weak.
Broncus Holding Corp. News
Broncus Wins EU MDR CE Mark for BroncTru Lung Catheter, Expanding Global Reach
An update from Broncus Holding Corp. ( ($HK:2216) ) is now available. Broncus Holding Corp. announced that its independently developed BroncTru disposable transbronchial puncture dilation catheter has obtained EU Medical
Broncus Ends Share Subscription Deals, Sees No Material Impact
Broncus Holding Corp. ( ($HK:2216) ) has provided an update. Broncus Holding Corporation has terminated previously announced share subscription agreements with two investors, entering into termination agreements with each subscriber
2216 FAQ
What was Broncus Holding Corp.’s price range in the past 12 months?
What is Broncus Holding Corp.’s market cap?
When is Broncus Holding Corp.’s upcoming earnings report date?
How were Broncus Holding Corp.’s earnings last quarter?
Is Broncus Holding Corp. overvalued?
Does Broncus Holding Corp. pay dividends?
What is Broncus Holding Corp.’s EPS estimate?
How many shares outstanding does Broncus Holding Corp. have?
What happened to Broncus Holding Corp.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Broncus Holding Corp.?
What is the TipRanks Smart Score and how is it calculated?
Broncus Holding Corp. Stock Smart Score
Company Description
Broncus Holding Corp.
Broncus Holding Corporation is a global medical technology company specializing in the development of interventional pulmonology products. Its market reach extends across Mainland China, the European Union, the United States, and other international territories. The company's innovative product lineup includes advanced navigation systems such as LungPoint Virtual Bronchoscopic Navigation, a sophisticated computer-assisted image-based software solution. It also offers LungPoint Plus, a system providing real-time airway guidance crucial for lung biopsies and other medical interventions, and LungPro, a virtual bronchoscopic navigation product that enables three-dimensional real-time guided transbronchial needle aspiration alongside proprietary parenchymal navigation. Beyond navigation, Broncus provides a suite of therapeutic products. These feature InterVapor, a targeted bronchoscopic thermal vapor ablation system designed to treat diseased, hyper-inflated lung segments. Additionally, it offers an RF Generator paired with an RF Ablation Catheter, forming a radiofrequency ablation system specifically developed to target lung cancer. The H-Marker, a pulmonary surgical marker, is another key offering. The company further supplies a range of specialized procedural devices, including the BioStarNeedle, a single-use ultrasound-guided aspiration needle for retrieving tissue samples, and the FleXNeedle, a versatile multipurpose biopsy needle. Complementing these are various bronchoscopic accessories like the Archimedes Sheath, a sterile, single-use flexible tube that serves as a working channel during bronchoscopic procedures. The Archimedes Dilation Balloon, another sterile, single-use flexible tube with a distal balloon, is used to dilate target lung tissue within the bronchial tree after insertion through a bronchoscope or sheath. Finally, the Steerable Sheath provides a steerable adjustment handle and an additional working channel. Broncus Holding Corporation was established in 2012 and maintains its corporate headquarters in Hangzhou, China.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Hong Xu
- Employees
- 195
- Website
- www.broncus.com
- Address
- Building 8, Hangzhou, ZH, 310051, CN
Broncus Holding Corp. (2216) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 4 | 15 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 0 | 0 | 12 |









